Research programme: cathepsin K inhibitors - Celera Group/Merck
Alternative Names: 39n; CRA-013783; L-006235; L-235Latest Information Update: 29 Aug 2011
At a glance
- Originator Celera Group; Merck & Co
- Developer Merck & Co
- Class Amides; Nitriles; Piperazines; Small molecules
- Mechanism of Action Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone cancer; Osteoporosis
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for Osteoporosis in Canada (PO)
- 29 Aug 2011 No development reported - Preclinical for Osteoporosis in USA (PO)
- 29 Aug 2011 No development reported for Bone cancer in USA (PO)